FGFR2 and biliary tract neoplasm: Currently potential therapeutic targets have been identified in nearly 40% of biliary tract cancers, with the most promising in iCCA patients including isocitrate dehydrogenase 1 (IDH1) and fibroblast growth factor receptor 2 (FGFR2) (9).